Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
Introduction: Immune checkpoint inhibitors (ICIs) are now standard of care in many cancers. They can generate immune-related adverse events (irAEs), but no biomarkers are available to identify patients who are more likely to develop irAEs. We assess the association between pre-existing autoantibodie...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2204754 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850238355485229056 |
|---|---|
| author | A Daban C Gonnin L Phan A Saldmann C Granier A Lillo-Lelouet C Le Beller J Pouchot l Weiss E Tartour E Fabre J Medioni S Oudard YA Vano MA Dragon-Durey A. Simonaggio |
| author_facet | A Daban C Gonnin L Phan A Saldmann C Granier A Lillo-Lelouet C Le Beller J Pouchot l Weiss E Tartour E Fabre J Medioni S Oudard YA Vano MA Dragon-Durey A. Simonaggio |
| author_sort | A Daban |
| collection | DOAJ |
| description | Introduction: Immune checkpoint inhibitors (ICIs) are now standard of care in many cancers. They can generate immune-related adverse events (irAEs), but no biomarkers are available to identify patients who are more likely to develop irAEs. We assess the association between pre-existing autoantibodies and occurrence of irAEs. Patients and Methods: We prospectively collected data from consecutive patients receiving ICIs for advanced cancers, in a single center between May 2015 and July 2021. Autoantibodies testing was performed before ICIs initiation including AntiNeutrophil Cytoplasmic Antibodies, Antinuclear Antibodies, Rheumatoid Factor anti-Thyroid Peroxidase and anti-Thyroglobulin. We analyzed the associations of pre-existing autoantibodies with onset, severity, time to irAEs and with survival outcomes. Results: Of the 221 patients included, most had renal cell carcinoma (n = 99; 45%) or lung carcinoma (n = 90; 41%). Grade ≥2 irAEs were more frequent among patients with pre-existing autoantibodies: 64 (50%) vs. 20 (22%) patients (Odds-Ratio= 3.5 [95% CI=1.8-6.8]; p < 0.001) in the positive vs negative group, respectively. irAEs occurred earlier in the positive group with a median time interval between ICI initiation and irAE of 13 weeks (IQR = 8.8-21.6) vs. 28.5 weeks (IQR=10.6-55.1) in the negative group (p = 0.01). Twelve patients (9.4%) experienced multiple (≥2) irAEs in the positive group vs. 2 (2%) in the negative group (OR = 4.5 [95% CI: 0.98-36], p = 0.04). After a median follow-up of 25 months, median PFS and OS were significantly longer among patients experiencing irAE (p = 0.00034 and p = 0.016, respectively). Conclusion: The presence of pre-existing autoantibodies is significantly associated with the occurrence of grade ≥2 irAEs, with earlier and multiple irAEs in patients treated with ICIs. |
| format | Article |
| id | doaj-art-d0872b5dc2fe4a1e840183a65eaab7ae |
| institution | OA Journals |
| issn | 2162-402X |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-d0872b5dc2fe4a1e840183a65eaab7ae2025-08-20T02:01:29ZengTaylor & Francis GroupOncoImmunology2162-402X2023-12-0112110.1080/2162402X.2023.2204754Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)A Daban0C Gonnin1L Phan2A Saldmann3C Granier4A Lillo-Lelouet5C Le Beller6J Pouchot7l Weiss8E Tartour9E Fabre10J Medioni11S Oudard12YA Vano13MA Dragon-Durey14A. Simonaggio15Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Paris, FranceDepartment of Immunology, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, FranceARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie; Hǒpital Européen Georges Pompidou, AP-HP. Centre – Université Paris Cité, Paris, FranceDepartment of Immunology, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, FranceDepartment of Immunology, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, FranceDepartment of Pharmacovigilance, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, FranceDepartment of Pharmacovigilance, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, FranceDepartment of Internal Medicine, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, FranceDepartment of Clinical Immunology, Hôpital Hôtel-Dieu, AP-HP.Centre – Université Paris Cité, Paris, FranceDepartment of Immunology, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, FranceINSERM U970, PARCC, Université Paris-Cité, Paris, FranceDepartment of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Paris, FranceDepartment of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Paris, FranceDepartment of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Paris, FranceDepartment of Immunology, Hôpital Européen Georges Pompidou, AP-HP.Centre – Université Paris Cité, Paris, FranceDepartment of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP.Centre – Université Paris Cité, Paris, FranceIntroduction: Immune checkpoint inhibitors (ICIs) are now standard of care in many cancers. They can generate immune-related adverse events (irAEs), but no biomarkers are available to identify patients who are more likely to develop irAEs. We assess the association between pre-existing autoantibodies and occurrence of irAEs. Patients and Methods: We prospectively collected data from consecutive patients receiving ICIs for advanced cancers, in a single center between May 2015 and July 2021. Autoantibodies testing was performed before ICIs initiation including AntiNeutrophil Cytoplasmic Antibodies, Antinuclear Antibodies, Rheumatoid Factor anti-Thyroid Peroxidase and anti-Thyroglobulin. We analyzed the associations of pre-existing autoantibodies with onset, severity, time to irAEs and with survival outcomes. Results: Of the 221 patients included, most had renal cell carcinoma (n = 99; 45%) or lung carcinoma (n = 90; 41%). Grade ≥2 irAEs were more frequent among patients with pre-existing autoantibodies: 64 (50%) vs. 20 (22%) patients (Odds-Ratio= 3.5 [95% CI=1.8-6.8]; p < 0.001) in the positive vs negative group, respectively. irAEs occurred earlier in the positive group with a median time interval between ICI initiation and irAE of 13 weeks (IQR = 8.8-21.6) vs. 28.5 weeks (IQR=10.6-55.1) in the negative group (p = 0.01). Twelve patients (9.4%) experienced multiple (≥2) irAEs in the positive group vs. 2 (2%) in the negative group (OR = 4.5 [95% CI: 0.98-36], p = 0.04). After a median follow-up of 25 months, median PFS and OS were significantly longer among patients experiencing irAE (p = 0.00034 and p = 0.016, respectively). Conclusion: The presence of pre-existing autoantibodies is significantly associated with the occurrence of grade ≥2 irAEs, with earlier and multiple irAEs in patients treated with ICIs.https://www.tandfonline.com/doi/10.1080/2162402X.2023.2204754Immune checkpoint inhibitorsimmune-related adverse eventspre-existing antibodies |
| spellingShingle | A Daban C Gonnin L Phan A Saldmann C Granier A Lillo-Lelouet C Le Beller J Pouchot l Weiss E Tartour E Fabre J Medioni S Oudard YA Vano MA Dragon-Durey A. Simonaggio Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs) OncoImmunology Immune checkpoint inhibitors immune-related adverse events pre-existing antibodies |
| title | Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs) |
| title_full | Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs) |
| title_fullStr | Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs) |
| title_full_unstemmed | Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs) |
| title_short | Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs) |
| title_sort | preexisting autoantibodies as predictor of immune related adverse events iraes for advanced solid tumors treated with immune checkpoint inhibitors icis |
| topic | Immune checkpoint inhibitors immune-related adverse events pre-existing antibodies |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2204754 |
| work_keys_str_mv | AT adaban preexistingautoantibodiesaspredictorofimmunerelatedadverseeventsiraesforadvancedsolidtumorstreatedwithimmunecheckpointinhibitorsicis AT cgonnin preexistingautoantibodiesaspredictorofimmunerelatedadverseeventsiraesforadvancedsolidtumorstreatedwithimmunecheckpointinhibitorsicis AT lphan preexistingautoantibodiesaspredictorofimmunerelatedadverseeventsiraesforadvancedsolidtumorstreatedwithimmunecheckpointinhibitorsicis AT asaldmann preexistingautoantibodiesaspredictorofimmunerelatedadverseeventsiraesforadvancedsolidtumorstreatedwithimmunecheckpointinhibitorsicis AT cgranier preexistingautoantibodiesaspredictorofimmunerelatedadverseeventsiraesforadvancedsolidtumorstreatedwithimmunecheckpointinhibitorsicis AT alillolelouet preexistingautoantibodiesaspredictorofimmunerelatedadverseeventsiraesforadvancedsolidtumorstreatedwithimmunecheckpointinhibitorsicis AT clebeller preexistingautoantibodiesaspredictorofimmunerelatedadverseeventsiraesforadvancedsolidtumorstreatedwithimmunecheckpointinhibitorsicis AT jpouchot preexistingautoantibodiesaspredictorofimmunerelatedadverseeventsiraesforadvancedsolidtumorstreatedwithimmunecheckpointinhibitorsicis AT lweiss preexistingautoantibodiesaspredictorofimmunerelatedadverseeventsiraesforadvancedsolidtumorstreatedwithimmunecheckpointinhibitorsicis AT etartour preexistingautoantibodiesaspredictorofimmunerelatedadverseeventsiraesforadvancedsolidtumorstreatedwithimmunecheckpointinhibitorsicis AT efabre preexistingautoantibodiesaspredictorofimmunerelatedadverseeventsiraesforadvancedsolidtumorstreatedwithimmunecheckpointinhibitorsicis AT jmedioni preexistingautoantibodiesaspredictorofimmunerelatedadverseeventsiraesforadvancedsolidtumorstreatedwithimmunecheckpointinhibitorsicis AT soudard preexistingautoantibodiesaspredictorofimmunerelatedadverseeventsiraesforadvancedsolidtumorstreatedwithimmunecheckpointinhibitorsicis AT yavano preexistingautoantibodiesaspredictorofimmunerelatedadverseeventsiraesforadvancedsolidtumorstreatedwithimmunecheckpointinhibitorsicis AT madragondurey preexistingautoantibodiesaspredictorofimmunerelatedadverseeventsiraesforadvancedsolidtumorstreatedwithimmunecheckpointinhibitorsicis AT asimonaggio preexistingautoantibodiesaspredictorofimmunerelatedadverseeventsiraesforadvancedsolidtumorstreatedwithimmunecheckpointinhibitorsicis |